Marcus Capital’s Global Blood Therapeutics GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
– Sell
-31,200
Closed -$969K – 44
2017
Q3
$969K Sell
31,200
-34,150
-52% -$960K 1.38% 32
2017
Q2
$1.79M Buy
65,350
+13,350
+26% +$397K 1.53% 32
2017
Q1
$1.92M Buy
52,000
+21,900
+73% +$552K 1.79% 28
2016
Q4
$435K Hold
30,100
– – 0.47% 43
2016
Q3
$694K Hold
30,100
– – 0.67% 44
2016
Q2
$499K Buy
+30,100
New +$607K 0.53% 45

Other funds holding GBT

Marcus Capital's GBT Position: Q4 2017 in Review

Marcus Capital sold out of Global Blood Therapeutics (GBT) in Q4 2017, closing a stake of 31,200 shares — an estimated $969K sold.

Marcus Capital first reported a position in GBT in Q2 2016 and held it in 6 quarters. The position peaked at $1.92M in Q1 2017. 157 funds tracked by Wall St. Rank hold GBT as of Q4 2017.

  • Marcus Capital reported no remaining Global Blood Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Marcus Capital sold 31,200 Global Blood Therapeutics shares in Q4 2017, an estimated $969K.
  • Marcus Capital first reported a position in Global Blood Therapeutics in Q2 2016 and held it in 6 quarters.
  • Marcus Capital's Global Blood Therapeutics position peaked at $1.92M in Q1 2017.
  • 157 funds tracked by Wall St. Rank held Global Blood Therapeutics as of Q4 2017.

Based on Marcus Capital's 13F filing for Q4 2017, filed 7 Feb 2018.